Navigation Links
Brown researchers make major signal transduction discovery
Date:10/4/2007

PROVIDENCE, R.I. [Brown University] The chemical process known as acetylation plays a central role in cytokine receptor signal transduction a fundamental biochemical cascade inside cells that controls the activity of antiviral and tumor-suppressing genes.

A team of cell biologists led by Eugene Chin, M.D., a research professor at The Warren Alpert Medical School of Brown University and a staff researcher at Rhode Island Hospital, reports its findings in the journal Cell. Their results are surprising.

Scientists have long known that phosphorylation, an amino acid modifying process in proteins, is critical for switching receptors on and off on the surface of cells. Chin and his team studied how type 1 interferon binds to a receptor complex, known as the IFN-α receptor, on the cell surface to trigger an immune response. Chin and his team found that acetylation, another chemical process that modifies amino acids, plays a central role in activating interferon receptors.

Interferons play a crucial role in the bodys defense against infection and uncontrolled cell growth. Type 1 interferon is widely used to treat hepatitis B and C and cancers such as melanoma and leukemia.

This is a major discovery in the field of signal transduction, Chin said. Tyrosine phosphorylation has so far been considered the major player in signal transduction. But what we discovered challenges this concept. We found another player acetylation in the process.

In their experiments, Chin and his team looked at how cells respond to type 1 interferon, a protein produced in response to a viral infection or other immune trigger. The researchers found that type 1 interferon receptors, which are found in every cell in the body, call up cytoplasmic CREB-binding protein, or CBP, to move up to the cell surface. CPB acetylates these receptors. That, in turn, sparks a biochemical cascade that attracts more proteins to create a complex called ISGF3. To activate this protein complex, Chin found, acetylation is required. Once that occurs, the complex travels to the cell nucleus to switch on anti-viral or tumor-suppressing genes.

The discovery of the acetylation of cytokine receptors marks a milestone in the study of signal transduction, the process of how cells receive and respond to chemical messages.

Many diseases, such as diabetes, cancer and heart disease, occur when signal transduction goes awry. That is why some drugs either inhibit or amplify signaling inside cells by targeting tyrosine phosphorylation. By showing that another chemical process is critical to signal transduction, Chins findings may explain why some anti-cancer or anti-viral drugs do not work for everyone. The findings provide an important new target for therapies that fight cancer and viral infectious diseases.


'/>"/>

Contact: Wendy Lawton
Wendy_Lawton@brown.edu
401-863-1862
Brown University
Source:Eurekalert

Related medicine news :

1. Wholly Ingrained: White or Brown? Food War Going Racist? Get to the Heart of the Matter
2. Louisiana Residents Warned Against Brown Recluse Spiders
3. Scientists Identify "master Switch" for Brown Fat in Mice
4. Researchers urge caution in using ear tube surgery
5. Researchers Scale to assess the Severity of Epilepsy in Kids
6. Researchers identify the early makers of Neonatal Sepsis
7. OHSU Researchers Announce New Discovery
8. Researchers Identify Gene Connected To Bipolar Disorder
9. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
10. Researchers trick Alzheimers Enzyme
11. Researchers find new HIV hiding place
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
(Date:5/26/2016)... , ... May 26, 2016 , ... On Memorial Day, ... women who lost their lives in military battle for the country. The nonprofit ... 2015 to provide more programs that empower independence for disabled military veterans, as well ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of ... today announced the organization has earned its ISO 13485 certification, indicating the company’s ... with all rules and policies associated with ISO quality standard 13485. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... and chief medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke ... was held during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice ... officer, today. In his new role, Marziani will lead the company,s business development and ... to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
(Date:5/24/2016)... May 24, 2016 Een app ... zodat zij collectief patiënten kunnen behandelen, hun kennis kunnen ... idee achter de nieuwe en revolutionaire MDLinking App, ontwikkeld ... Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... inmiddels beschikbaar is, wordt op dinsdag 24 mei officieel ...
Breaking Medicine Technology: